Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

Bibliography

• Stahl SM. Stahl's essential psychopharmacology. 3rd edition. Cambridge University, Press, Cambridge; 2008
   Google Scholar
• Nestler EJ, Barrot M, DiLeone RJ, Neurobiology of depression. Neuron 2002;34:13-25
   PubMed Web of Science ®Google Scholar
• Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009;124:195-206
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Dhir A. sigma-1 receptors in major depression and anxiety. Expert Rev Neurother 2009;9:1021-34
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004;18:269-84
   PubMed Web of Science ®Google Scholar
• Fishback JA, Robson MJ, Xu YT, Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther 2010;127:271-82
   PubMed Web of Science ®Google Scholar
• Walker JM, Bowen WD, Walker FO, Sigma receptors: biology and function. Pharmacol Rev 1990;42:355-402
   PubMed Web of Science ®Google Scholar
• Yao H, Yang Y, Kim KJ, Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood 2010;115:4951-62
   PubMed Web of Science ®Google Scholar
• Marrazzo A, Caraci F, Salinaro ET, Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport 2005;16:1223-6
   PubMed Web of Science ®Google Scholar
• Palmer CP, Mahen R, Schnell E, Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res 2007;67:11166-75
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma1 receptor ligand. Expert Opin Ther Targets 2008;12:45-58
   PubMed Web of Science ®Google Scholar
• Su TP, Hayashi T, Maurice T, The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010;31:557-66
   PubMed Web of Science ®Google Scholar
• Yoon SY, Roh DH, Seo HS, An increase in spinal dehydroepiandrosterone sulfate (DHEAS) enhances NMDA-induced pain via phosphorylation of the NR1 subunit in mice: involvement of the sigma-1 receptor. Neuropharmacology 2010;59:460-7
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhao Y, Luan W, Sigma-1 receptors amplify dopamine D1 receptor signaling at presynaptic sites in the prelimbic cortex. Biochim Biophys Acta 2010;1803:1396-408
   PubMed Web of Science ®Google Scholar
• Kitaichi K, Chabot JG, Moebius FF, Expression of the purported sigma1 (σ1) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. J Chem Neuroanat 2000;20:375-87
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci USA 2004;101:14949-54
   PubMed Web of Science ®Google Scholar
• Diaz JL, Zamanillo D, Corbera J, Selective sigma-1 (σ1) receptor antagonists: emerging target for the treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009;9:172-83
   PubMedGoogle Scholar
• Klouz A, Said DB, Ferchichi H, Protection of cellular and mitochondrial functions against liver ischemia by N-benzyl-N′-(2-hydroxy-3,4-dimethoxybenzyl)-piperazine (BHDP), a sigma1 ligand. Eur J Pharmacol 2008;578:292-9
   PubMed Web of Science ®Google Scholar
• Hall AA, Herrera Y, Ajmo CT Jr, Sigma receptors suppress multiple aspects of microglial activation. Glia 2009;57:744-54
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007;131:596-610
   PubMed Web of Science ®Google Scholar
• Pal A, Chu UB, Ramachandran S, Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor. J Biol Chem 2008;283:19646-56
   PubMed Web of Science ®Google Scholar
• Aydar E, Palmer CP, Klyachko VA, The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002;34:399-410
   PubMed Web of Science ®Google Scholar
• Hayashi T, Rizzuto R, Hajnoczky G, MAM: more than just a housekeeper. Trends Cell Biol 2009;19:81-8
   PubMed Web of Science ®Google Scholar
• Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005;74:739-89
   PubMed Web of Science ®Google Scholar
• Ha Y, Dun Y, Thangaraju M, Sigma receptor 1 modulates ER stress in retinal neurons. Invest Ophthalmol Vis Sci 2011;52:527-40
   PubMed Web of Science ®Google Scholar
• Yang S, Bhardwaj A, Cheng J, Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2. Anesth Analg 2007;104:1179-84
   PubMed Web of Science ®Google Scholar
• Cobos EJ, del Pozo E, Baeyens JM. Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J Neurochem 2007;102:812-25
   PubMed Web of Science ®Google Scholar
• Megalizzi V, Decaestecker C, Debeir O, Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines. Eur J Cancer 2009;45:2893-905
   PubMed Web of Science ®Google Scholar
• Luty AA, Kwok JB, Dobson-Stone C, Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 2010;68:639-49
   PubMed Web of Science ®Google Scholar
• Rizzuto R, Pozzan T. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev 2006;86:369-408
   PubMed Web of Science ®Google Scholar
• Fontanilla D, Johannessen M, Hajipour AR, The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009;323:934-7
   PubMed Web of Science ®Google Scholar
• Herrera Y, Katnik C, Rodriguez JR, sigma-1 receptor modulation of ASIC1a channels and ASIC1a-induced Ca2+ influx in rat cortical neurons. J Pharmacol Exp Ther 2008;327:491-502
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein ML, Andersen KA, The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 2010;167:247-55
   PubMed Web of Science ®Google Scholar
• Hayashi T, Fujimoto M. Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. Mol Pharmacol 2010;77:517-28
   PubMed Web of Science ®Google Scholar
• Sharma P, Ignatchenko V, Grace K, Endoplasmic reticulum protein targeting of phospholamban: a common role for an N-terminal di-arginine motif in ER retention? PLoS One 2010;5:e11496
   PubMed Web of Science ®Google Scholar
• Roh DH, Yoon SY, Seo HS, Sigma-1 receptor-induced increase in murine spinal NR1 phosphorylation is mediated by the PKCalpha and epsilon, but not the PKCzeta, isoforms. Neurosci Lett 2010;477:95-9
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Matsumoto RR, Thompson TL, Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 1989;4:254-8
   PubMed Web of Science ®Google Scholar
• Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett 2008;440:19-22
   PubMed Web of Science ®Google Scholar
• Nakano M, Osada K, Misonoo A, Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. Life Sci 2010;86:309-14
   PubMed Web of Science ®Google Scholar
• Tuerxun T, Numakawa T, Adachi N, SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression. Neurosci Lett 2010;469:303-8
   PubMed Web of Science ®Google Scholar
• Li L, Xu B, Zhu Y, DHEA prevents Abeta25–35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling. Neuropharmacology 2010;59:323-33
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-64
   PubMed Web of Science ®Google Scholar
• Hayashi T, Justinova Z, Hayashi E, Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J Pharmacol Exp Ther 2010;332:1054-63
   PubMed Web of Science ®Google Scholar
• Bhuiyan MS, Tagashira H, Shioda N, Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. Expert Opin Ther Targets 2010;14:1009-22
   PubMed Web of Science ®Google Scholar
• Liu Y, Matsumoto RR. Alterations in fos-related antigen 2 and σ1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: time course and regional distribution studies. J Pharmacol Exp Ther 2008;327:187-95
   PubMed Web of Science ®Google Scholar
• Houry WA, Frishman D, Eckerskorn C, Identification of in vivo substrates of the chaperonin GroEL. Nature 1999;402:147-54
   PubMed Web of Science ®Google Scholar
• Csermely P, Soti C, Blatch GL. Chaperones as parts of cellular networks. Adv Exp Med Biol 2007;594:55-63
   PubMed Web of Science ®Google Scholar
• Tsai SY, Hayashi T, Harvey BK, Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci USA 2009;106:22468-73
   PubMed Web of Science ®Google Scholar
• Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther 2010;332:388-97
   PubMed Web of Science ®Google Scholar
• Kong AN, Owuor E, Yu R, Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 2001;33:255-71
   PubMed Web of Science ®Google Scholar
• Sala C, Cambianica I, Rossi F. Molecular mechanisms of dendritic spine development and maintenance. Acta Neurobiol Exp (Wars) 2008;68:289-304
   PubMed Web of Science ®Google Scholar
• van Spronsen M, Hoogenraad CC. Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep 2010;10:207-14
   PubMed Web of Science ®Google Scholar
• Tashiro A, Minden A, Yuste R. Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. Cereb Cortex 2000;10:927-38
   PubMed Web of Science ®Google Scholar
• Zhang H, Macara IG. The polarity protein PAR-3 and TIAM1 cooperate in dendritic spine morphogenesis. Nat Cell Biol 2006;8:227-37
   PubMed Web of Science ®Google Scholar
• Tolias KF, Bikoff JB, Burette A, The Rac1-GEF Tiam1 couples the NMDA receptor to the activity-dependent development of dendritic arbors and spines. Neuron 2005;45:525-38
   PubMed Web of Science ®Google Scholar
• Takemoto-Kimura S, Ageta-Ishihara N, Nonaka M, Regulation of dendritogenesis via a lipid-raft-associated Ca2+/calmodulin-dependent protein kinase CLICK-III/CaMKIgamma. Neuron 2007;54:755-70
   PubMed Web of Science ®Google Scholar
• Tsai SY, Hayashi T, Zhang Y, Insights to the Sigma-1 receptor chaperone's cellular functions: a microarray report. Soc Neurosci Abstr 2010;136:21
   Google Scholar
• Marchetti C, Tafi E, Middei S, Synaptic adaptations of CA1 pyramidal neurons induced by a highly effective combinational antidepressant therapy. Biol Psychiatry 2010;67:146-54
   PubMed Web of Science ®Google Scholar
• Hajszan T, MacLusky NJ, Leranth C. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur J Neurosci 2005;21:1299-303
   PubMed Web of Science ®Google Scholar
• Sweet RA, Fish KN, Lewis DA. Mapping synaptic pathology within cerebral cortical circuits in subjects with schizophrenia. Front Hum Neurosci 2010;4:44
   PubMed Web of Science ®Google Scholar
• Tackenberg C, Ghori A, Brandt R. Thin, stubby or mushroom: spine pathology in Alzheimer's disease. Curr Alzheimer Res 2009;6:261-8
   PubMed Web of Science ®Google Scholar
• Luebke JI, Weaver CM, Rocher AB, Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models. Brain Struct Funct 2010;214:181-99
   PubMed Web of Science ®Google Scholar
• Tsai J, Grutzendler J, Duff K, Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004;7:1181-3
   PubMed Web of Science ®Google Scholar
• Stephens B, Mueller AJ, Shering AF, Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005;132:741-54
   PubMed Web of Science ®Google Scholar
• Zaja-Milatovic S, Milatovic D, Schantz AM, Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005;64:545-7
   PubMed Web of Science ®Google Scholar
• Dietz DM, Dietz KC, Nestler EJ, Molecular mechanisms of psychostimulant-induced structural plasticity. Pharmacopsychiatry 2009;42(Suppl 1):S69-78
   PubMed Web of Science ®Google Scholar
• Antonini V, Prezzavento O, Coradazzi M, Anti-amnesic properties of (+/–)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. J Neurochem 2009;109:744-54
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007;32:514-21
   PubMed Web of Science ®Google Scholar
• Iyo M, Shirayama Y, Watanabe H, Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1072-3
   PubMed Web of Science ®Google Scholar
• Niitsu T, Shirayama Y, Fujisaki M, Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1345-6
   PubMed Web of Science ®Google Scholar
• Skuza G, Rogoz Z. Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice. Pharmacol Rep 2009;61:1179-83
   PubMed Web of Science ®Google Scholar
• Sabino V, Cottone P, Parylak SL, Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res 2009;198:472-6
   PubMed Web of Science ®Google Scholar
• Wang L, Duncan G. Silencing of sigma-1 receptor induces cell death in human lens cells. Exp Cell Res 2006;312:1439-46
   PubMed Web of Science ®Google Scholar
• Prezzavento O, Campisi A, Parenti C, Synthesis and resolution of cis-(±)-methyl (1R,2S/1S,2R)-2-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)cyclopropanecarboxylate [(±)-PPCC)]: new σ receptor ligands with neuroprotective effect. J Med Chem 2010;53:5881-5
   PubMed Web of Science ®Google Scholar
• Goyagi T, Goto S, Bhardwaj A, Neuroprotective effect of sigma1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. Stroke 2001;32:1613-20
   PubMed Web of Science ®Google Scholar
• Pahl HL, Baeuerle PA. The ER-overload response: activation of NF-κB. Trends Biochem Sci 1997;22:63-7
   PubMed Web of Science ®Google Scholar
• Katayama T, Imaizumi K, Manabe T, Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 2004;28:67-78
   PubMed Web of Science ®Google Scholar
• Chafekar SM, Hoozemans JJ, Zwart R, Abeta1–42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid Redox Signal 2007;9:2245-54
   PubMed Web of Science ®Google Scholar
• Ryu EJ, Harding HP, Angelastro JM, Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 2002;22:10690-8
   PubMed Web of Science ®Google Scholar
• Smith WW, Jiang H, Pei Z, Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 2005;14:3801-11
   PubMed Web of Science ®Google Scholar
• Nishitoh H, Kadowaki H, Nagai A, ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 2008;22:1451-64
   PubMed Web of Science ®Google Scholar
• Jomova K, Vondrakova D, Lawson M, Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010;345:91-104
   PubMed Web of Science ®Google Scholar
• Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010;460:525-42
   PubMed Web of Science ®Google Scholar
• Meunier J, Gue M, Recasens M, Attenuation by a sigma1 (sigma1) receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats. Br J Pharmacol 2004;142:689-700
   PubMed Web of Science ®Google Scholar
• Mishina M, Ishiwata K, Ishii K, Function of sigma1 receptors in Parkinson's disease. Acta Neurol Scand 2005;112:103-7
   PubMed Web of Science ®Google Scholar
• Jansen KL, Faull RL, Storey P, Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res 1993;623:299-302
   PubMed Web of Science ®Google Scholar
• Toyohara J, Sakata M, Ishiwata K. Imaging of sigma1 receptors in the human brain using PET and [11C]SA4503. Cent Nerv Syst Agents Med Chem 2009;9:190-6
   PubMedGoogle Scholar
• Müller MJ, Grunder G, Wetzel H, Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res 1999;89:275-80
   PubMed Web of Science ®Google Scholar
• Huber MT, Gotthardt U, Schreiber W, Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry 1999;32:68-72
   PubMed Web of Science ®Google Scholar
• Frieboes RM, Murck H, Wiedemann K, Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 1997;132:82-8
   PubMed Web of Science ®Google Scholar
• Modell S, Naber D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry 1996;29:63-6
   PubMed Web of Science ®Google Scholar
• Gilligan PJ, Kergaye AA, Lewis BM, Piperidinyltetralin sigma ligands. J Med Chem 1994;37:364-70
   PubMed Web of Science ®Google Scholar
• Gewirtz GR, Gorman JM, Volavka J, BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 1994;10:37-40
   PubMed Web of Science ®Google Scholar
• Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol Bull 1991;27:103-6
   PubMedGoogle Scholar
• Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry 2004;37(Suppl 3):S214-20
   PubMed Web of Science ®Google Scholar
• Weissman AD, Casanova MF, Kleinman JE, Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54
   PubMed Web of Science ®Google Scholar
• Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic cerebral cortices. Neurochem Res 1992;17:983-90
   PubMed Web of Science ®Google Scholar
• Uchida N, Ujike H, Nakata K, No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies. BMC Psychiatry 2003;3:13
   PubMed Web of Science ®Google Scholar
• Holoubek G, Muller WE. Specific modulation of sigma binding sites by the anxiolytic drug opipramol. J Neural Transm 2003;110:1169-79
   PubMed Web of Science ®Google Scholar
• Möller HJ, Volz HP, Reimann IW, Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001;21:59-65
   PubMed Web of Science ®Google Scholar
• Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 2005;10:319-23
   PubMed Web of Science ®Google Scholar
• Gatti F, Bellini L, Gasperini M, Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996;153:414-16
   PubMed Web of Science ®Google Scholar
• Serretti A, Lattuada E, Zanardi R, Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Res 2000;94:185-90
   PubMed Web of Science ®Google Scholar
• Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 2004;5:2053-8
   PubMed Web of Science ®Google Scholar
• Silver H, Barash I, Aharon N, Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000;15:257-61
   PubMed Web of Science ®Google Scholar
• Neznamov GG, Siuniakov SA, Chumakov DV, Clinical study of the selective anxiolytic agent afobazole. Eksp Klin Farmakol 2001;64:15-9
   PubMedGoogle Scholar
• Takebayashi M, Kagaya A, Uchitomi Y, Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short communication. J Neural Transm 1998;105:537-42
   PubMed Web of Science ®Google Scholar
• Uzunova V, Sheline Y, Davis JM, Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95:3239-44
   PubMed Web of Science ®Google Scholar
• van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology 2003;165:97-110
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Keebler A, Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646-9
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Roberts E, Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41:311-18
   PubMed Web of Science ®Google Scholar
• Bloch M, Schmidt PJ, Danaceau MA, Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533-41
   PubMed Web of Science ®Google Scholar
• Roze C, Bruley Des Varannes S, Shi G, Inhibition of prostaglandin-induced intestinal secretion by igmesine in healthy volunteers. Gastroenterology 1998;115:591-6
   PubMed Web of Science ®Google Scholar
• Pande AC, Geneve J, Scherrer B. Igmesine, a novel sigma ligand, has antidepressant properties. In Congress of Collegium Internationale Neuro-Psychopharmacologicum; Glasgow, UK; 1998, CINP [Abstract S.03.01]
   Google Scholar
• Paschos KA, Veletza S, Chatzaki E. Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression. CNS Drugs 2009;23:755-72
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Brunswick DJ, Hundert M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A – a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1333-8
   PubMed Web of Science ®Google Scholar
• Urfer R, Takao K, Sato W, SA4503 is a potent and selective sigma-1 receptor agonist in clinical development for depression and stroke recovery. Soc Neurosci Abstr 2009;496:3
   Google Scholar
• de Paulis T. Drug evaluation: Vilazodone – a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs 2007;10:193-201
   PubMed Web of Science ®Google Scholar
• Nimura T, Ando T, Yamaguchi K, The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study. J Neurosurg 2004;100:606-10
   PubMed Web of Science ®Google Scholar
• Mishina M, Ohyama M, Ishii K, Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 2008;22:151-6
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Sakata M, Ishii K, High occupancy of σ1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 2009;12:1127-31
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex. Neurosci Lett 1993;163:129-31
   PubMed Web of Science ®Google Scholar
• Uchida N, Ujike H, Tanaka Y, A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer's disease. Am J Geriatr Psychiatry 2005;13:1062-6
   PubMed Web of Science ®Google Scholar
• Maruszak A, Safranow K, Gacia M, Sigma receptor type 1 gene variation in a group of Polish patients with Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:432-8
   PubMed Web of Science ®Google Scholar
• Rosen H. Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs Today (Barc) 2008;44:661-8
   PubMed Web of Science ®Google Scholar
• Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist 2007;13:272-93
   PubMed Web of Science ®Google Scholar
• Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-D-aspartate receptor antagonist in the management of pain. CNS Drug Rev 2007;13:96-106
   PubMedGoogle Scholar
• Miyatake R, Furukawa A, Matsushita S, Functional polymorphisms in the sigma1 receptor gene associated with alcoholism. Biol Psychiatry 2004;55:85-90
   PubMed Web of Science ®Google Scholar
• Inada T, Iijima Y, Uchida N, No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: a collaborative study by the Japanese genetics initiative for drug abuse. Ann N Y Acad Sci 2004;1025:27-33
   PubMed Web of Science ®Google Scholar
• Maurice T, Casalino M, Lacroix M, Involvement of the sigma1 receptor in the motivational effects of ethanol in mice. Pharmacol Biochem Behav 2003;74:869-76
   PubMed Web of Science ®Google Scholar
• Sabino V, Cottone P, Zhao Y, The σ-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology 2009;34:1482-93
   PubMed Web of Science ®Google Scholar
• Stefanski R, Justinova Z, Hayashi T, Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology 2004;175:68-75
   PubMed Web of Science ®Google Scholar
• Takahashi S, Horikomi K, Kato T. MS-377, a novel selective sigma1 receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. Eur J Pharmacol 2001;427:211-19
   PubMed Web of Science ®Google Scholar
• Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988;240:219-21
   PubMed Web of Science ®Google Scholar
• Navarro G, Moreno E, Aymerich M, Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci USA 2010;107:18676-81
   PubMed Web of Science ®Google Scholar
• Davidson J, Miller R, Wingfield M, The first clinical study of BW-234U in schizophrenia. Psychopharmacol Bull 1982;18:173-6
   PubMedGoogle Scholar
• Chouinard G, Annable L. An early phase-II clinical-trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacol 1984;84:282-4
   Web of Science ®Google Scholar
• Guy W, Manov G, Wilson WH, Psychotropic actions of BW-234U in the treatment of inpatient schizophrenics – a dose-range study. Drug Dev Res 1983;3:245-52
   Web of Science ®Google Scholar
• Schwarcz G, Halaris A, Dren A, Open label evaluation of the novel antipsychotic compound BW234U in chronic-schizophrenics. Drug Dev Res 1985;5:387-93
   Web of Science ®Google Scholar
• Gerlach K, Uhlig T, Plathof J, Effects of opipramol as an evening anaesthesiologic premedication. Neuropsychobiol 2002;46:161-6
   PubMed Web of Science ®Google Scholar
• Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998;18:208-11
   PubMed Web of Science ®Google Scholar